Conduct a physiologically-based pharmacokinetic modeling /simulation or a clinical pharmacokinetics trial to evaluate the effect of repeat doses of a moderate CYP3A4 inhibitor on the single dose pharmacokinetics of neratinib and its active metabolites to assess the magnitude of increased drug exposure and to